The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
Other factors such as state-level laws, insurance networks, or cultural preferences likely explain the remaining variance in brand preference across US counties, according to researchers Rachel D. Melamed, PhD, and Andrey Rzhetsky, PhD, of the University of Chicago. They concluded that a “patchwork” of contrasting medication cultures is in place across the nation, showing “geographically separated sub-Americas” that demonstrate the influences of racial composition, state-level healthcare laws, and wealth.
Their findings are based on an analysis of Truven MarketScan medical claims data covering more than 150 million individuals (nearly half the country’s population), followed for up to 10 years (2003-2013). The authors focused on comparing prescription rates of the 598 most highly prescribed drugs in more than 2300 US counties. The data contain a total of approximately 36 million patient-years.
Among the study’s findings are the following:
The study was funded by the DARPA Big Mechanism program and by National Institutes of Health grants.
Reference
Melamed RD, Rzhetsky A. Patchwork of contrasting medication cultures across the USA. Nature Communications.2018;9:4022. doi: 10.1038/s41467-018-06205-1.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.